Search

Iniparib Improves Survival in Metastatic Triple-Negative Breast Cancer

Iniparib Improves Survival in Metastatic Triple-Negative Breast Cancer

Patients who received iniparib (Sanofi-aventis) plus gemcitabine (Gemzar; Eli Lilly) and carboplatin survived an average of almost 5 months longer than those treated with chemotherapy alone.